30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Squire Patton Boggs promotes partner to head Europe IP&T practice

1 May 2026 The IP expert will use his new role to support clients in cross-border challenges driven by innovation, digitalisation, market pressure and regulatory change.

Americas

From the courtroom: Hikma v Amarin SCOTUS oral arguments

30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.

Europe

Report: 85% of in-house counsel want IP service providers to embrace AI

30 April 2026 Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.